On September 17, 2018, Galera Therapeutics, Inc. closed the transaction. The series C oversubscribed round of funding was led by new investor Clarus Ventures, LLC, and new investors Adage Capital Management, L.P., HBM Healthcare Investments AG (SWX:HBMN), a fund co-managed by HBM Partners Ltd. and nebag ag (SWX:NBEN), Nan Fung Life Sciences, RA Capital Management, LLC, Rock Springs Capital, Tekla Capital Management LLC, existing investors Correlation Ventures, New Enterprise Associates, Novartis Venture Fund, a fund managed by Novartis Venture Funds, Sofinnova Ventures, Inc. and Novo Holdings A/S, and Galera Angels. In all 23 investors were involved in the round.

As part of the transaction, Emmett T. Cunningham of Clarus Ventures, LLC will join the company's board of directors.